Functionalized liposomes for targeted breast cancer drug delivery  

作　　者：Janske Nel Kamil Elkhoury Émilie Velot Arnaud Bianchi Samir Acherar Grégory Francius Ali Tamayol Stéphanie Grandemange Elmira Arab-Tehrany 

机构地区：[1]Universitéde Lorraine,LIBio,F-54000,Nancy,France [2]LAAS-CNRS,F-31400,Toulouse,France [3]Universitéde Lorraine,CNRS,IMoPA,F-54000,Nancy,France [4]Universitéde Lorraine,CNRS,LCPM,F-54000,Nancy,France [5]Universitéde Lorraine,CNRS,LCPME,F-54000,Nancy,France [6]Department of Biomedical Engineering,University of Connecticut Health Center,Farmington,CT,06030,USA [7]Universitéde Lorraine,CNRS,CRAN,F-54000,Nancy,France

出　　处：《Bioactive Materials》2023年第6期401-437,共37页生物活性材料（英文）

摘　　要：Despite the exceptional progress in breast cancer pathogenesis,prognosis,diagnosis,and treatment strategies,it remains a prominent cause of female mortality worldwide.Additionally,although chemotherapies are effective,they are associated with critical limitations,most notably their lack of specificity resulting in systemic toxicity and the eventual development of multi-drug resistance(MDR)cancer cells.Liposomes have proven to be an invaluable drug delivery system but of the multitudes of liposomal systems developed every year only a few have been approved for clinical use,none of which employ active targeting.In this review,we summarize the most recent strategies in development for actively targeted liposomal drug delivery systems for surface,transmembrane and internal cell receptors,enzymes,direct cell targeting and dual-targeting of breast cancer and breast cancer-associated cells,e.g.,cancer stem cells,cells associated with the tumor microenvironment,etc.

关 键 词：Liposomes Breast cancer Anti-cancer agents Targeted drug delivery Surface functionalization Receptor-targeted drug delivery 

分 类 号：R737.9[医药卫生—肿瘤]